Evidence map›Paper›PMID 42255863›Full record

ArticleCureus2026

Definitive Radiotherapy in Serous Carcinoma of Unknown Primary With Isolated Nodal Disease: A Case Review.

Nneoma Uzoukwu, Enrique Hernandez, Israh Akhtar, Jeremy Price

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nneoma UzoukwuObstetrics, Gynecology, and Reproductive Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, USA.
Enrique HernandezObstetrics, Gynecology, and Reproductive Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, USA.
Israh AkhtarPathology and Laboratory Medicine, Temple University Hospital, Philadelphia, USA.
Jeremy PriceRadiation Oncology, Temple University Hospital, Philadelphia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous carcinoma (HGSC) is an aggressive malignancy that may arise from the endometrium, ovary, fallopian tube, or peritoneum, but in rare cases, the primary site remains unknown. Isolated nodal presentation is particularly uncommon, and in such cases, it is inferred to be metastasis. Serous carcinoma of unknown primary (SCUP) lacks management guidelines, with treatment often extrapolated from other gynecologic cancers. We describe the case of a woman with isolated inguinal and pelvic nodal SCUP who achieved durable disease control with definitive radiotherapy after progression on endocrine therapy. An 88-year-old woman presented with a large left inguinal mass. Biopsy demonstrated HGSC of Müllerian origin. She was initiated on tamoxifen 20 mg twice a day; however, after seven months, the inguinal mass enlarged, and CA-125 levels increased from 2,691 U/mL to 4,191 U/mL. Given her frailty and the morbidity associated with resecting nodes with clinical extracapsular extension, the patient underwent definitive external beam radiotherapy (55 Gy/25 fractions to involved nodes; 45 Gy/25 fractions to the ipsilateral groin and hemipelvis). Six months after radiotherapy, CT showed a reduction of the inguinal mass and pelvic sidewall lymph node, with CA-125 levels declining to 19 U/mL. The patient has remained without disease progression by imaging and CA-125 for 30 months following completion of radiotherapy. This case describes an uncommon presentation of HGSC of Mullerian origin with isolated inguinal nodes in the absence of identifiable uterine, adnexal, or peritoneal primary. In the absence of established guidelines, it demonstrates the feasibility of definitive radiotherapy in achieving durable disease control.

Indexed as

endosalpingiosishigh-grade serous carcinomanodal diseaseradiation therapyunknown primary

Identifiers

PMID42255863
PMCPMC13240969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.